{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:24Z","timestamp":1788815364912,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104816","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:28:33Z","timestamp":1781911713000},"page":"104816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1104-7866","authenticated-orcid":false,"given":"Vanda","family":"Salutari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-6815","authenticated-orcid":false,"given":"Elena","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-1195","authenticated-orcid":false,"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Ghizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2872-7852","authenticated-orcid":false,"given":"Sara","family":"Lardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7035","key":"10.1016\/j.ijgc.2026.104816_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ijgc.2026.104816_bib2","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1021\/ja101495v","article-title":"Transcription inhibition by platinum-DNA cross-links in live mammalian cells","volume":"132","author":"Ang","year":"2010","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104816_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104816_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104816_bib5","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104816_bib6","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104816_bib7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"10.1016\/j.ijgc.2026.104816_bib8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104816_bib9","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1535-7163.MCT-11-0597","article-title":"Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models","volume":"11","author":"Clark","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104816_bib10","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"8","key":"10.1016\/j.ijgc.2026.104816_bib11","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","article-title":"Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors","volume":"25","author":"Balma\u00f1a","year":"2014","journal-title":"Ann Oncol"},{"issue":"45","key":"10.1016\/j.ijgc.2026.104816_bib12","doi-asserted-by":"crossref","first-page":"79175","DOI":"10.18632\/oncotarget.16577","article-title":"Phase I\/Ib study of olaparib and carboplatin in women with triple negative breast cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104816_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104816_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ijgc-2018-000035","article-title":"Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients","volume":"29","author":"Rivkin","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104816_bib15","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104816_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104816_bib17","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104816_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","article-title":"Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","volume":"148","author":"Gray","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104816_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/bjc.2016.41","article-title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor Rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","volume":"114","author":"Drew","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104816_bib20","first-page":"S2","article-title":"Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)Gynecol","volume":"176","author":"Westin","year":"2023","journal-title":"Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104816_bib21","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2024.42.16_suppl.5506","article-title":"Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer","volume":"42","author":"Lheureux","year":"2024","journal-title":"The NEO trialJ Clin Oncol."},{"issue":"25","key":"10.1016\/j.ijgc.2026.104816_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104816_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104533","article-title":"Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1\/2 mutation type and site: a multicenter real-world study","volume":"10","author":"Marchetti","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104816_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/2767-9764.CRC-22-0423","article-title":"The PARP1 inhibitor AZD5305 impairs ovarian adenocarcinoma progression and visceral metastases in patient-derived xenografts alone and in combination with carboplatin","volume":"3","author":"Dellavedova","year":"2023","journal-title":"Cancer Res Comm"},{"key":"10.1016\/j.ijgc.2026.104816_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:48:40Z","timestamp":1788814120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26003476"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104816","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104816"}}